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ABSTRACT 
Acute-on-chronic liver failure (ACLF) is a recently recognized syndrome in cirrhosis characterized by acute 
decompensation (AD), organ failure(s) and high short-term mortality. Organ failure(s) is defined by the CLIF-
SOFA score or by its simplified version CLIF-OF score. They include 6 types of organ failure (liver, renal, 
coagulation, cerebral, respiratory and circulatory) failure.  One third of patients hospitalized with AD present 
with ACLF at admission or develop ACLF during hospitalization. ACLF frequently occurs in closed 
relationship to a precipitating event. According to the number of organ failures, ACLF is graded into three 
stages (ACLF-1: single renal failure or single non-renal organ failure if associated to renal dysfunction and/or 
cerebral dysfunction, ACLF-2: 2 organ failures and ACLF-3: 3-6 organ failures) with increasing 28-day 
mortality rate (from 23% to 74%). ACLF may develop at any phase during the clinical course of the disease. 
Patients without prior AD develop a severe form of ACLF.   
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CIRRHOSIS AS A MULTIORGAN DISEASE 
The clinical course of cirrhosis is traditionally divided into two phases1: Compensated cirrhosis defines the 
time period between the onset of cirrhosis and the first major complication. During this period (10-15 years) 
patients have no or minor symptoms, but histological liver lesions and portal pressure steadily progresses if 
the etiological factor of cirrhosis persists. The term decompensated cirrhosis is used following the 
development of ascites, variceal hemorrhage and/or hepatic encephalopathy. Decompensated cirrhosis is 
associated with a short survival (3-5 years).  
In addition to liver failure, cirrhotic patients with decompensated cirrhosis present several extra-hepatic 
organ function abnormalities that complicate the clinical course of the disease. Renal dysfunction is the most 
frequent. It is characterized by renal sodium retention, which plays a major role in the pathogenesis of 
ascites, an impaired renal ability to excrete water, which is the cause of dilutional hyponatremia (an 
excessive total body sodium diluted by a greater proportion of retained water) and hepato-renal syndrome2.  
Two types of HRS have been identified3. Type 2 HRS is characterized by moderate and steady impairment 
in renal perfusion and GFR and increase in serum creatinine. It is the main cause of refractory ascites. In 
contrast, type 1-HRS consists in a rapidly progressive impairment in renal perfusion and GFR and severe 
renal failure. Type 1 HRS is associated with a high probability of death within days or 1-2 weeks.  
Renal dysfunction and HRS occurs in the setting of a profound impairment of circulatory function due to 
selective splanchnic arterial vasodilation2. In compensated cirrhosis and initial phases of decompensated 
cirrhosis the reduced systemic vascular resistance is compensated by an increase in cardiac output 
(hyperdynamic circulation). However, as the disease advances there is a progressive decrease in cardiac 
chronotropic function and left ventricular inotropic function (cirrhotic cardiomiopathy) and cardiac output4. 
The net effect of both processes, operating simultaneously, is a reduction in effective arterial blood volume 
and marked activation of the renin-angiotensin system, sympathetic nervous system and antidiuretic 
hormone to maintain arterial pressure within limits compatible with life. Despite the activation of these 
vasoconstrictor systems, arterial hypotension is a common finding in these patients. 
Patients with decompensated cirrhosis, particularly those with severe complications such as sepsis, are 
prone to develop relative adrenal insufficiency, a syndrome in which the adrenal secretion of cortisol is 
insufficient to cover the peripheral demands5. The mechanism is complex and may be related to a defect at 
the three levels of cortisol secretion, the hypothalamus, the hypophysis and the adrenal glands. Cortisol is 
essential for the vascular response to endogenous vasoconstrictors (angiotensin 2 and norepinephrine). Not 
surprisingly relative adrenal insufficiency is associated to severe impairment in circulatory function and 
hepatorenal syndrome.   
Vasodilation is also an important feature in the pulmonary circulation. It develops by the release of local 
vasodilators to allocate the increase in cardiac output.  When pulmonary vasodilation is severe, there is 
impairment in the ventilation/perfusion ratio and patients develop hypoxia and dyspnea (hepatopulmonary 
syndrome)6. 
Brain dysfunction is by frequency the second extra-hepatic organ dysfunction in cirrhosis. It ranges from 
minimal hepatic encephalopathy to hepatic coma. The circulating levels of ammonia and other endogenous 
substances that inhibit cerebral function are increased in cirrhosis, and play a major role in the pathogenesis 
of brain dysfunction7. Impairment in cerebral perfusion and local inflammation, which potentiates the toxic 
effect of ammonia, may play a contributory role. 
In addition to the digestion and absorption of nutrients, one of the major functions of the intestines is to 
allocate trillions of bacteria without significant adverse effects. A complex process that includes the intestinal 
production of antibacterial molecules, the barrier effect of the intestinal mucosa and an effective local 
immune system prevents the translocation of bacteria and bacterial products from the intestinal lumen to the 
systemic circulation8. This function is severely impaired in cirrhosis9. Translocation of viable bacteria from 
the intestinal lumen to the systemic circulation is the mechanisms of endogenous bacterial infections 
(spontaneous bacteremia and peritonitis). On the other hand there is also translocation of bacterial products 
(lypopolysaccharide, bacterial DNA and other pathogen associated molecular patterns) without viable 
bacteria that causes chronic systemic inflammation. A recent hypothesis proposes that translocation of 
bacteria and bacterial product is in the origin of multi-organ dysfunction in cirrhosis10. Inflammation would 
initially be allocated in splanchnic area, leading to arterial vasodilation and contributing to the development 
of portal hypertension and circulatory dysfunction. As intestinal dysfunction progresses inflammation 
became systemic and affects the peripheral organs. Inflammation impairs organ function by two different 
mechanism. The first is by causing arterial vasodilation. However, the second and perhaps the most 
important is organ inflammation. Inflammation decreases organ function by impairing organ microcirculation, 
mitochondrial function and cell function and by increasing cell death. 
THE CONCEPT OF ACLF  
The concept of Acute-on-Chronic Liver Failure (ACLF) was introduced for the first time by Jalan and 
Williams in 200211 to define an acute syndrome that develops in patients with compensated cirrhosis in close 
chronological relationship to a precipitating event and characterized by multi-organ failure and high short-
term mortality. Following this paper Williams several other proposals for the diagnostic criteria of ACLF have 
been suggested.  
R. Jalan and R. Williams proposal (2002)11   
Acute deterioration in liver function over a period of 2-4 weeks in a patient with well compensated cirrhosis, 
usually associated to a precipitating event (hepatotoxic: superimposed hepatitis viral infection, drug-induced 
liver injury, hepatotoxins or excessive alcohol consumption; extra-hepatic: variceal bleeding or sepsis), 
leading to severe deterioration in clinical status with jaundice and hepatic encephalopathy and/or HRS.  
Asian Pacific Association for the Study of the Liver (APASL) proposal (2004-2009)12,13 
 ACLF is an acute direct hepatic insult (hepatotropic viral infections, active alcohol consumption or drug-
induced liver injury) that causes liver failure [jaundice (serum bilirubin ≥ 5 mg/dl) and coagulopathy (INR≥1.5 
or prothrombine activity < 40%)] complicated within 4 weeks by clinical ascites and/or encephalopathy in a 
patient with previously diagnosed or undiagnosed chronic liver disease/cirrhosis. Both compensated 
cirrhosis and non-cirrhotic chronic liver disease (NAFLD-related chronic hepatic injury or chronic hepatitis 
with significant fibrosis or significant fibrosis due to other reasons) qualify as chronic liver disease. Bacterial 
infections are not considered hepatic insults. Patients with cirrhosis and known prior decompensation 
(jaundice, encephalopathy or ascites) developing acute deterioration in clinical status related or unrelated to 
precipitating events are considered as acute decompensation but not ACLF.  
North-American Consortium for the Study of End Stage Liver Disease (NACSELD) proposal (only for 
infected patients) (2014)14  
Patients with decompensated cirrhosis and bacterial infections developing 2 organ failures: grade III-IV 
hepatic encephalopathy, septic shock or need for mechanical ventilation or renal replacement therapy 
qualify as organ failure. 
American Association for the Study of Liver Diseases (AASLD)/European Association for the Study 
of the(EASL) proposal (2014)15  
ACLF is an acute deterioration of a pre-existing chronic liver disease (compensated or decompensated 
cirrhosis) usually related to a precipitating event (including bacterial infections) and associated with 
increased mortality at 3 months due to multi-organ failure. 
European Association for the Study of the Liver- Chronic Liver Failure Consortium (EASL-CLIF 
Consortium) proposal (2013-2015)16,17.  
The methodology used for the above mentioned proposals were similar and consisted in two steps. The first 
was the elaboration of a definition and diagnostic criteria of ACLF based on personal opinions or consensus 
agreement among experts. Subsequently, the proposal was tested in retrospective studies in patient 
cohorts. Not surprisingly, this methodology determined major discrepancies among proposals. Due to this 
lack of agreement between proposals and the subjectivity in the methodology used for the elaboration of 
these definitions, investigators from the EASL-CLIF Consortium decided apply a more pragmatic approach 
to define ACLF. They designed a prospective multicenter observational investigation in 1343 patients 
hospitalized in 29 European Hospitals for the treatment of an acute decompensation of cirrhosis aimed to 
define ACLF in cirrhosis and to propose diagnostic criteria (CANONIC Study)17. At the time of patient 
enrolment, important clinical data from 3 months prior to enrolment were retrospectively obtained.  
Thereafter, patients were prospectively studied at enrolment and during a 28-day follow-up period by a pre-
specified detailed protocol. Finally, data on liver transplantation, patient survival and causes of death were 
obtained during one year.  
Pre-defined assumptions 
Three assumptions had to be taken for the study design and data analysis. They were based on the 
experience of the investigators and on prior proposals. 
1. ACLF may develop in patients with or without prior history of acute decompensation.  ACLF development, 
however, always occurs in the setting of acute decompensation (ascites, encephalopathy, gastrointestinal 
hemorrhage and/or bacterial infections).  
2. Extrahepatic failure(s) is a major differential feature of the syndrome.  
3. ACLF is associated with high short-term mortality (arbitrarily defined as a 28-day mortality rate greater 
than 15% after diagnosis).  
Therefore, acute decompensation, organ failure(s) and high short-term mortality rate were the predefined 
characteristics of the syndrome. All other features (definition, prevalence, diagnostic criteria of organ failure, 
diagnostic criteria of ACLF, precipitating events, clinical course, ACLF grades, prognosis, and potential 
mechanism) were obtained after a detailed analysis of the CANONIC database.  
Diagnostic criteria of organ failure   
The Chronic Liver Failure SOFA score (CLIF-SOFAs) was the original scale used to define organ failures in 
the CANONIC Study (Table 1). It derived from Sequential Organ Failure Assessment score (SOFAs), a 
scale widely used for the diagnosis of organ failures and to predict short-term mortality in intensive care18, 
adapted to liver patients. Adaptation was made based on prior studies and on the clinical experience of the 
CANONIC investigators.  Cut-off values were established after assessing the risk increase of 28-day 
mortality rate in each category compared to that of the previous one using the CANONIC database. A 
simplified version of the CLIF-SOFAs, the CLIF Consortium Organ Failure score (CLIF-C OFs)19, with 
identical criteria to diagnose organ failure and similar prognostic accuracy, has been incorporated into new 
prognostic scores for ACLF (Table 2). The CLIF-SOFAs and the CLIF-OFs score showed similar prognostic 
values as MELDs in the overall patients included in the CANONIC study. 
Liver failure, was defined by a serum bilirubin level ≥ 12 mg/dl.  As indicated this threshold was based on 
short-term mortality criteria. Renal failure was defined by a serum creatinine level ≥ 2 mg/dl or the use of 
renal replacement therapy. The reason to use this serum creatinine threshold of serum creatinine levels in 
cirrhosis  is that relatively low increases of serum creatinine levels in decompensated cirrhosis indicates 
marked reduction in GFR, and that there is a large body of evidence indicating that serum creatinine levels 
over this cut-off are associated with poor prognosis. Cerebral failure was defined by grade 3 or 4 hepatic 
encephalopathy according to the West Haven classification. Coagulation failure was defined be an INR> 2.5 
and/or a platelet count ≤109 (platelet count was not included to define coagulation failure in the CLIF-OFs). 
INR was included because it is widely used in cirrhosis and has been validated as an important prognostic 
marker. Circulatory failure was defined by the use of vasoconstrictors (norepinephrine, epinephrine, 
dopamine, dobutamine or terlipressin) to increase arterial pressure. Respiratory failure was defined by a 
ratio of partial pressure of arterial oxygen to FiO2 of ≤ 200 or by a SpO2 to FiO2 ratio ≤ 214. The possibility of 
using SpO2 to FiO2 ratio was offered because arterial catheterization is not a standard procedure in patients 
with cirrhosis admitted to regular wards. 
Table 3 shows the prevalence and number of organ failures in the patients included in the CANONIC study. 
Organ failure was present in 33% of the patients. Most patients had single organ failure. Liver failure was the 
most frequent organ failure observed followed by renal, coagulation, cerebral, circulatory and respiratory 
failure. 
Diagnostic criteria of ACLF and ACLF grades 
Patients without organ failure showed very low 28-day transplant-free mortality rate (4.6%). In the remaining 
patients mortality increased according to the number of organ failures (table 4). Patients with one organ 
failure showed a mortality rate 3 folds higher than patients without organ failure but it was lower than the 
predefined-mortality rate of 15% required for the diagnosis of ACLF. Therefore, a refinement in the 
prognostic assessment of patients with single organ failure looking for additional risk factors had to be 
performed. The type of organ failure was clearly a risk factor in these patients. It was higher than 15% in 
patients with kidney failure (18.6%), but lower than 15% (10%-13.9%) in those with single “non-kidney” 
organ failure. We, therefore, further compared additional factors included in the CLIF-SOFAs between 
patients with single organ failure who did and did not survive for 28 days. Significant differences were found 
only in serum creatinine levels and in the prevalence of grade 1 or 2 hepatic encephalopathy (West Haven 
classification). The presence of a serum creatinine between 1.5 and 1.9 and of moderate hepatic 
encephalopathy were defined as renal  and cerebral dysfunction, respectively (as indicated the terms renal 
and cerebral failures are applied to patients with serum creatinine ≥ 2 mg/dl or with grade 3-4 hepatic 
encephalopathy). Table 4 shows the 28-day mortality rate after grouping the patients according to these 
prognostic markers. It was low in patients without ACLF or with single non-renal organ failure without renal 
and/or cerebral dysfunction. In patients with single renal failure or with single non-renal organ failure if 
associated to renal dysfunction or hepatic encephalopathy was well above the predefined cut-of level of 
15%. The 28-day transplant free mortality rate after enrolment in patients with 2  and 3 organ failures were 
32% and 78.6%, respectively. In summary, 3 different risk factors obtained by the CLIF-SOFAs at enrolment 
were used to identify the subgroups of patients with decompensated cirrhosis with ACLF: 1. The presence of 
2 organ failures or more; 2. The presence of one organ failure when the organ that fails was the kidney; and 
3. The coexistence of a single “non-kidney” organ failure with kidney dysfunction and/or cerebral 
dysfunction.  
Based on these criteria, patients with decompensated cirrhosis were stratified into 4 groups. 
ACLF grade 1. ACLF grade 1 is diagnosed with one of the following: 1/ Single kidney failure; 2/Single liver, 
coagulation, circulatory or lungs failure associated with serum creatinine between 1.5 and 2 mg/dL and/or 
hepatic encephalopathy grades 1 or 2; 3/ single cerebral failure with serum creatinine between 1.5 and 2 
mg/dL. 
ACLF grade 2.   ACLF grade 2 is diagnosed when there are two organ failures, whatever the combination is. 
ACLF grade 3. ACLF grade 3 is diagnosed when there are three or more organ failures.  
No ACLF. With these diagnostic criteria, patients with cirrhosis without ACLF are those patients who either 
do not have any organ failure, have single organ failure but not involving the kidneys with serum creatinine < 
1.5 mg/dl and no hepatic encephalopathy, or single cerebral failure with serum creatinine < 1.5 mg/dL. 
According to data from the CANONIC study, approximately one fourth (23%) of patients admitted to hospital 
for an acute decompensation of the disease had ACLF at admission. Furthermore, 11% of the patients 
without ACLF at enrolment developed the syndrome during hospitalization which gives a total prevalence of 
ACLF in patients admitted to hospital with decompensated cirrhosis of 31%.  Among ACLF patients, 51% 
had ALCF grade 1, 35% ACLF grade 2, and 13% ACLF grade 3. Besides providing the diagnosis of the 
syndrome, these diagnostic criteria also provide data for rapid prognostic information. In patients without 
ACLF mortality is low, 1.9% and 10% for 28-day and 90-day mortality, respectively. By contrast, mortality is 
higher in patients with ACLF (33% and 51%, respectively) and parallels ACLF grades: 23% and 41%, 31% 
and 55%, and 74% and 78%, in grades 1, 2, and 3, respectively. 
The usefulness of these classification criteria as well as that of CLIF-SOFA and CLIF-OF scores in 
assessing prognosis has been validated in independent series of patients20-23. Nonetheless, these criteria 
may require future refining.  
CLINICAL CHARACTERISTICS 
The CANONIC study provided relevant clinical information regarding the characteristics of the syndrome in 
Europe (table 5)16. Patients with ACLF were younger and more frequently alcoholics than patients without 
ACLF. Clinically detectable ascites was present in approximately 80% of patients with ACLF. However if 
clinically detectable ascites and surrogates of ascites (diuretic treatment prior or after admission and 
paracentesis or SBP prior to admission) are considered together, the vast majority of patients (98%) had 
evidences of ascites.  Among the laboratory data, the most relevant were a significantly increased blood 
white cell count (WCC) and C reactive protein in comparison to patients with decompensated cirrhosis but 
without ACLF suggesting that ACLF develops in the setting of systemic inflammation. Bacterial infection and 
active alcoholism, which are important mechanisms of systemic inflammation, were the most frequent 
precipitating events. However, no identifiable precipitating event was recognized in approximately 40% of 
patients. Among bacterial infections, spontaneous bacterial peritonitis (SBP), sepsis and pneumonia were 
more frequently associated to ACLF than other infections. The presence and type of precipitating events 
was not related with mortality, indicating that once ACLF develops, prognosis depends more on the number 
of organ failures than on the trigger. Kidney failure was the most prevalent organ failure in ACLF-1. For 
ACLF-2 liver failure is the most prevalent followed by kidney, cerebral and coagulation failure. For ACLF 
grade 3, the prevalence of all organ failures is high (table 6). Previous history of episodes of acute 
decompensation was absent in 23% of patients with ACLF, indicating that development of ACLF as the 
initial manifestation of decompensated cirrhosis is a relatively common feature. These patients without prior 
history of decompensation were younger, more frequently alcoholics, had more severe systemic 
inflammation and grade of ACLF and higher short-term mortality than patients with ACLF and prior history of 
acute decompensation.  
Li et al have recently reported the characteristics of ACLF in 890 consecutive patients with HBV associated 
cirrhosis and AD using the diagnostic criteria derived from the CANONIC Study24. Their results indicate that 
ACLF associated to HBV infection in China is similar to ACLF associated to alcoholism or chronic hepatitis C 
in Europe although with some peculiarities. The prevalence of ACLF in the Chinese study was higher (40%) 
than in the CANONIC series, with ACLF-2 being the most frequent ACLF grade followed by ACLF 1 and 3. 
Liver and coagulation failures were the commonest organ failures. The most frequent precipitating event 
was bacterial infections followed by reactivation of hepatitis B and active alcoholism. In half of patients no 
precipitating event were identified. As in the CANONIC study, patients with ACLF showed systemic 
inflammation independently on the type of precipitating event. Mortality rates (28-day and 90-day) in patients 
with no ACLF, ACLF and ACLF grades 1, 2 and 3 were similar to those in CANONIC series. Fifty-per-cent of 
patients had no prior AD episodes. Mortality was unrelated to the presence or type of precipitating events or 
prior history of AD.  
 
ABBREVIATIONS  
ACLF                           acute-on-chronic liver failure  
AD                               acute decompensation   
CANONIC                   EASL-CLIF Acute on Chronic Liver Failure Study  
CLIF                           chronic Liver Failure;  
CLIF-C OFs               CLIF-consortium organ failure score  
CLIF-SOFAs              CLIF-sequential organ failure assessment score  
CRP                           C-reactive protein;   
E                                epinephrine  
EASL                         European association for the study of the liver 
FIO2                           fraction of inspired oxygen  
HBV                           hepatitis B virus;   
HE                             hepatic encephalopathy  
INR                            international normalized ratio 
MELDs,                     model of end-stage liver disease score 
NE                             norepinephrine 
PAMPs                      pathogen-associated molecular patters   
PaO2                         partial pressure of arterial oxygen  
SOFA                       sequential organ failure assessment;  
SpO2                        pulse oximetric saturation 
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Table 1. The Chronic Liver Failure (CLIF)-Sequential Organ Failure Assessment (SOFA) Score 
Organ/system 0 1 2 3 4 
Liver 
 (Bilirubin, mg/dL)           
<1.2 ≥1.2 - ≤2.0 ≥2.0 - <6.0 ≥6.0 - <12.0 ≥12 
 
Kidney 
(Creatinine, mg/dL)      
 
<1.2 
 
≥1.2 - <2.0 
 
≥2.0 - <3.5b                           ≥3.5 - <5.0                        ≥5.0 
or use of renal-replacement therapy 
 
Cerebral (HE grade)             
 
No HE 
 
 
I 
 
II 
 
IIIc 
 
IV 
Coagulation (INR)                
 
<1.1 ≥1.1 – <1.25 ≥1.25 - <1.5 ≥1.5 – <2.5 ≥2.5 or 
Platelets20x109/Ld 
 
Circulation  
(MAP mm Hg)          
 
 
≥70 
 
<70 
 
Dopamine ≤5 or 
Dobutamine or 
Terlipressine 
 
Dopamine >5 or 
E ≤ 0.1 or 
NE ≤ 0.1 
 
Dopamine >15 or 
E > 0.1 or 
NE > 0.1 
Lungs  
PaO/FiO2:  
or  
SpO2/FiO2 
 
>400 
 
>512 
 
>300 - ≤400 
 
>357 - ≤512 
 
>200 - ≤300 
 
>214 - ≤357 
 
>100 - ≤200 
 
>8 - ≤214f 
 
≤100 
 
≤89 
 Like the SOFA score, the CLIF-SOFA score includes sub-scores ranging from 0 to 4 for each of six components (liver, kidneys, brain, coagulation, 
circulation, and lungs) with higher scores indicating more severe organ impairment. Aggregated scores range from 0 to 24 and provide information on 
overall severity. HE denotes hepatic encephalopathy, INR, International Normalized Ratio; MAP, mean arterial pressure; E, epinephrine; NE, 
norepinephrine, PaO2, partial pressure of arterial oxygen; FIO2, fraction of inspired oxygen; SpO2, pulse oximetric saturation. The highlighted area in light 
blue shows the diagnostic criteria for organ failures.  The shaded area describes criteria for diagnosis of organ failure. 
 
Table 2.  CLIF-Organ Failure score system. Risk increase with respect to low-risk category (Odds Ratio, OR, and 95% 
Confidence Interval, CI) for each organ system sub-score. 
Organ / System Sub-score = 1 Sub-score = 2 Sub-Score = 3 
Liver 
OR vs Sub-score 1 (95%CI) 
Bilirubin < 6mg/dL 
 
6 ≤ Bilirubin ≤ 12mg/dL 
OR: 2·6 (1·6 – 4·3) 
Bilirubin >12mg/dL 
OR: 7·1 (4·7 – 10·7) 
Kidney 
 
OR vs Sub-score 1 (95%CI) 
Creatinine <2mg/dL 2 ≤ Creatinine<3·5 mg/dL 
 
OR: 3·8 (2·3 – 6·3) 
Creatinine≥3·5 mg/dL 
or renal replacement 
OR: 15·5 (8·9 – 26·8) 
Brain 
(West-Haven grade for HE) 
OR vs Sub-score 1 (95%CI) 
Grade 0 Grade 1-2 
 
OR: 2·1 (1·4 – 3·2) 
Grade 3-4 * 
 
OR: 9·7 (5·9 – 16·1) 
Coagulation 
OR vs Sub-score 1 (95%CI) 
INR < 2·0 2·0 ≤ INR < 2·5 
OR: 5·2 (3·4 – 7·9) 
INR ≥ 2·5 
OR: 7·5 (4·6 – 12·3) 
Circulatory 
OR vs Sub-score 1 (95%CI) 
MAP ≥70 mm/Hg MAP <70 mm/Hg 
OR: 2·6 (1·6 – 4·3) 
Use of vasopressors 
OR: 9·2 (5·2 – 16·4) 
Respiratory  
PaO2/FiO2 
or 
SpO2/FiO2 
OR vs Sub-score 1 (95%CI) 
 
>300 
 
>357 
 
≤300 - > 200 
 
>214- ≤357 
OR: 2·7 (1·7 – 4·2) 
 
≤200 (#) 
 
≤214 (#) 
OR: 6·4 (3·1 – 13·2) 
The shaded area describes criteria for diagnosing organ failures 
HE: Hepatic Encephalopathy. FIO2, fraction of inspired oxygen. PaO2, partial pressure of arterial oxygen. SpO2, pulse oximetric saturation.  MAP: Mean 
arterial pressure 
* Patients submitted to Mechanical Ventilation (MV) due to HE and not to a respiratory failure were considered as presenting a cerebral failure (cerebral 
sub-score=3).  
# Other patients enrolled in the study with MV were considered as presenting a respiratory failure (respiratory sub-score=3).  
Table 3. Prevalence and number of organ failures 
 Patients (n=1,343) Prevalence (%) 
Number of organ failures   
No organ failure 901 67.1 
One organ failure 287 21.4 
Two organ failures  108 8.0 
3-6 Organ failures 47 3.5 
Type of organ failure   
Liver failure 207 15.4 
Renal failure 169 12.6 
Coagulation failure 105 7.8 
Cerebral failure 99 7.4 
Circulatory failure 64 4.8 
Respiratory failure 32 2.4 
 
  
 Table 4. Diagnosis and grades of ACLF (CANONIC study) 
 TX-free patients  
(n=1,287) 
28-Day mortality 
rate 
ACLF grades 
No organ failure 879 (68.3%) 39/879 (4.4%) 
 No ACLF 
Single non-renal failure,  creatinine<1.5 mg/dLm, no HE 128 (9.9%) 8/128 (6.3%) 
Single renal failure 86 (6.7%) 16/86 (18.6%) 
 ACLF-1 
Single non-renal failure, Creatinine 1.5-1.9 mg/dLm and/or HE 54 (4.1%) 15/54 (27.7%) 
2 organ failures 97 (7.5%) 31/97 (32.0%)  ACLF-2 
3 organ failures 25 (1.9%) 17/25 (68.0%) 
 ACLF-3 
4-6 organ failures 18 (1.4%) 12/18 (88.9%) 
HE: Hepatic encephalopathy
Table 5. Patients’ Characteristics at Enrollment 
 
 
 
Characteristic 
 
 
No ACLF 
(N=1040) 
 
ACLF  
All Grades 
(N= 303) 
 
 
 
P valuea 
 
ACLF 
Grade 1 
(N=148) 
 
ACLF 
Grade 2 
(N=108) 
 
ACLF 
Grade 3 
(N=47) 
 
 
 
P valueb 
Age (yr) 58±12 56±11 0.02 58±12 54±11 52±12 <0.01 
Ascites  656 (63.4) 236 (78.7) <0.001 112 (76.2) 87 (82.1) 37 (78.7) 0.08 
MAP (mm/Hg)c 85±12 79±13 <0.001 81±13 79±13 72±10 <0.001 
Cause of cirrhosis        
   Alcohol 483 (49.2) 170 (60.3) <0.01 86 (61.9) 64(59.8) 26 (56.5) <0.01 
   Hepatitis C 210 (21.4) 38 (13.0) <0.01 15 (10.8) 17 (15.9) 6 (13.0) 0.01 
   Alcohol plus hepatitis C 95 (9.7) 27 (9.3) 0.83 14 (10.1) 9 (8.5) 4 (8.7) 0.97 
Potential precipitating events of ACLF        
   Bacterial infection  226 (21.8) 98 (32.6) <0.001 44 (29.9) 33 (30.8) 21 (44.7) <0.001 
   Gastrointestinal hemorrhage 180 (17.3) 40 (13.2) 0.09 15 (10.1) 14 (13.0) 11 (23.4) 0.06 
   Active alcoholismd 147 (14.9) 69 (24.5) <0.001 22 (16.1) 28 (28.6) 19 (40.4) <0.001 
   Other precipitating evente 34 (3.5) 25 (8.6) <0.001 12 (8.5) 10 (9.6) 3 (6.7) <0.01 
   No precipitating eventf 584 (58.9) 126 (43.6) <0.001 73 (51.4) 40 (40.0) 13 (27.3) <0.001 
   >1 Precipitating eventg 56 (5.7) 39 (13.5) <0.001 17 (12.0) 14 (14.0) 8 (17.0) <0.001 
Organ failure       
   Liver  75 (7.2) 132 (43.6) <0.001 37 (25.2) 65 (60.2) 30 (63.8) <0.001 
   Kidney 0 (0) 169 (55.8) <0.001 87 (58.8) 49 (45.4) 33 (70.2) <0.001 
   Cerebral 26 (2.5) 73 (24.1) <0.001 5 (3.4) 35 (32.4) 33 (70.2) <0.001 
   Coagulation 21 (2.0) 84 (27.7) <0.001 11 (7.4) 42 (38.9) 31 (66.0) <0.001 
   Circulation  13 (1.3) 51 (16.8) <0.001 3 (2.0) 18 (16.7) 30 (63.8) <0.001 
   Lungs  4 (0.4) 28 (9.2) <0.001 5 (3.4) 7 (6.5) 16 (34.0) <0.001 
Kidney dysfunction 96 (9.2) 40 (13.2) 0.04 26 (17.6) 8 (7.4) 6 (12.8) 0.01 
Cerebral dysfunction 254 (24.6) 108 (35.9) <0.001 74 (50.3) 25 (23.1) 9 (19.6) <0.001 
Laboratory data       
   Hematocrit (%) 31±6 29±6 <0.001 29±6 29±5 27±7 <0.001 
   Platelet count (x109/L) 110±76 100±69 0.02 107±73 98±67 77±56 0.01 
   Serum bilirubin (mg/dL) 4.8±6.8 12.8±17.7 <0.001 7.7±9.2 15..2±11.1 23.2±35.9 <0.001 
   INRh 1.5±0.4 2.1±0.9 <0.001 1.7±0.6 2.3±0.9 2.8±1.0 <0.001 
   Alanine aminotransferase (U/L) 55±123 67±118 0.14 44±53 65±121 169±217 <0.001 
   Aspartate aminotransferase (U/L) 93±148 143±268 <0.01 80±70 132±174 377±580 <0.001 
   Serum creatinine (mg/dL) 1.0±0.4 2.3±1.6 <0.001 2.4±1.4 2.1±1.8 2.6±1.7 <0.001 
   Serum sodium (mmol/L) 135±6 133±6 <0.001 133±7 133±6 134±7 <0.001 
Time from previous decompensation        
   No previous decompensation 279 (27.8) 66 (23.2) 0.12 21 (16.5) 27 (27.6) 18 (42.9) <0.01 
      Less than 3 months 102 (10.8) 47 (17.6)  
0.02 
23 (18.1) 14 (14.3) 10 (23.8)  
<0.01       From 3 to 12 months 165 (17.4) 43 (17.1) 21 (16.5) 19 (19.4) 3 (7.1) 
      More than 12 months 402 (42.8) 111 (41.6) 62 (48.8) 38 (38.8) 11 (26.2) 
Data are are means±SD or number of patients (%).  
aP value of comparisons between patients with and without ACLF 
bP value of comparisons across ACLF Grades (No ACLF, ACLF grade 1, ACLF grade 2 and ACLF grade 3). 
cMean Arterial Pressure 
dActive alcoholism was defined by more than 14 drinks per week in women and more than 21 drinks per week in men within 3 months prior to study 
enrolment.20 
eOther precipitating event was defined by the presence of one of the following: transjugular intrahepatic porto-systemic shunting, major surgery, 
therapeutic paracentesis without use of intravenous albumin, hepatitis, or alcoholic hepatitis (liver biopsy required for diagnosis). 
fNo precipitating event denotes the absence of bacterial infection, active alcoholism, or other precipitating event. 
g More than one precipitating event denotes the presence of at least two of these: bacterial infection, active alcoholism, or other precipitating event.  
hInternational Normalised Ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
